BMY has reported somewhat disappointing results for 2025, and the investors' disappointment is evident in the breakdown of the double top that had formed. This suggests a likely drop of about 10% in the stock price, although it doesn't affect the long term. The weaker sales in generic drugs should be offset by additional cost reductions, but nobody likes holding stocks that rely on cutting costs...
We suggest a short-term sell to take advantage of this 10% drop and then wait to see how BMY's price reacts.
交易結束：達到停損點
A fake breakout happened, this is a bull signal that moved the price to the opposite side of the channel. 
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。